0001214659-21-000756.txt : 20210125 0001214659-21-000756.hdr.sgml : 20210125 20210125163145 ACCESSION NUMBER: 0001214659-21-000756 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210121 FILED AS OF DATE: 20210125 DATE AS OF CHANGE: 20210125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Johnson Craig A CENTRAL INDEX KEY: 0001370348 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 21549972 MAIL ADDRESS: STREET 1: C/O PURE BIOSCIENCE STREET 2: 1725 GILLESPIE WAY CITY: EL CAJON STATE: CA ZIP: 92020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-51235.xml PRIMARY DOCUMENT X0306 4 2021-01-21 0001576263 Mirati Therapeutics, Inc. MRTX 0001370348 Johnson Craig A C/O MIRATI THERAPEUTICS INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 true false false false Common Stock 2021-01-21 4 M false 15000 20.54 A 18475 D Common Stock 2021-01-21 4 S false 3505 210.0056 D 14970 D Common Stock 2021-01-21 4 S false 3183 210.8088 D 11787 D Common Stock 2021-01-21 4 S false 4562 211.9359 D 7225 D Common Stock 2021-01-21 4 S false 3372 212.9748 D 3853 D Common Stock 2021-01-21 4 S false 44 213.62 D 3809 D Common Stock 2021-01-21 4 S false 334 214.7532 D 3475 D Non Qualified Stock Option (right to buy) 20.54 2021-01-21 4 M false 15000 0 D 2024-09-08 Common Stock 15000 0 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. This transaction was executed in multiple trades at prices ranging from $209.37 to $210.355. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $210.39 to $211.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $211.40 to $212.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $212.52 to $213.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $214.62 to $215.065. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. /s/ Vickie Reed, Attorney-in-Fact 2021-01-25